Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
ELOXATIN |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Alkylating agent (organoplatinum complex). |
| Generic Name |
|
Oxaliplatin 5mg/mL; soln for IV infusion after dilution; preservative-free. |
| Indications |
|
Adjuvant treatment for Stage III colon cancer in patients who have undergone complete resection of the primary tumor (in combination with infusional 5-FU/LV). Advanced carcinoma of the colon or rectum (in combination with infusional 5-FU/LV). |
| Children |
|
Not recommended. |
| Adults |
|
See literature. Premedicate with antiemetics. Give by IV infusion every two weeks for a total of 6 months (eg, 12 cycles). Day 1: 85mg/m2 followed by leucovorin + 5-FU. Day 2: Leucovorin followed by 5-FU. Neuropathy, other toxicities: see literature for dose adjustments. |
| Precautions |
|
Have epinephrine, corticosteroids, antihistamines available during infusion. Discontinue if interstitial lung disease or pulmonary fibrosis suspected. Monitor for neuropathy. Renal impairment. Monitor WBCs with differential, hemogloblin, platelets, blood chemistries (including ALT, AST, bilirubin, creatinine) before each treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Interactions |
|
Caution with concomitant nephrotoxic agents. Monitor oral anticoagulants. |
| Adverse Reactions |
|
Peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, GI upset, increased liver enzymes, fatigue, stomatitis; hypersensitivity reactions, pulmonary fibrosis (may be fatal), hepatotoxicity. |
| How Supplied |
|
Single-use vials (50mg, 100mg, 200mg)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
